Arbutus Biopharma Corp Cash Flow-to-Debt Ratio
Arbutus Biopharma Corp cash flow-to-debt ratio. Arbutus Biopharma Corp (ABUS) has a Cash Flow-to-Debt Ratio of -0.39x as of June 2026, meaning its operating cash flow of $-6.02 Million could theoretically repay 0% of its total liabilities ($15.29 Million) in one year. Check ABUS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Arbutus Biopharma Corp (1998–2025)
Cash flow-to-debt ratio of Arbutus Biopharma Corp from 1998 to 2025. Historical debt coverage capacity for Arbutus Biopharma Corp across 28 annual periods. Check ABUS total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Arbutus Biopharma Corp Cash Flow-to-Debt Ratio by Year (1998–2025)
Arbutus Biopharma Corp cash flow-to-debt ratio by year from 1998 to 2025. Year-by-year debt coverage analysis for Arbutus Biopharma Corp. For the full cash flow conversion analysis, see ABUS operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.20x | $-39.64 Million | $18.04 Million | ▼ -16.3% |
| 2024 | -1.89x | $-64.85 Million | $34.34 Million | ▲ +15.7% |
| 2023 | -2.24x | $-85.94 Million | $38.38 Million | ▼ -270.9% |
| 2022 | -0.60x | $-35.36 Million | $58.57 Million | ▲ +68.7% |
| 2021 | -1.93x | $-67.53 Million | $35.05 Million | ▼ -31.5% |
| 2020 | -1.46x | $-51.44 Million | $35.11 Million | ▲ +32.3% |
| 2019 | -2.17x | $-71.01 Million | $32.79 Million | ▲ +11.8% |
| 2018 | -2.45x | $-67.90 Million | $27.67 Million | ▼ -176.2% |
| 2017 | -0.89x | $-48.60 Million | $54.70 Million | ▼ -11.9% |
| 2016 | -0.79x | $-57.88 Million | $72.90 Million | ▼ -138.6% |
| 2015 | -0.33x | $-54.78 Million | $164.61 Million | ▲ +19.1% |
| 2014 | -0.41x | $-12.42 Million | $30.20 Million | ▲ +23.6% |
| 2013 | -0.54x | $-6.74 Million | $12.52 Million | ▼ -118.9% |
| 2012 | 2.85x | $33.27 Million | $11.68 Million | ▲ +421.9% |
| 2011 | -0.89x | $-7.52 Million | $8.50 Million | ▲ +19.0% |
| 2010 | -1.09x | $-11.25 Million | $10.29 Million | ▼ -35.8% |
| 2009 | -0.80x | $-5.24 Million | $6.51 Million | ▲ +61.6% |
| 2008 | -2.09x | $-8.48 Million | $4.05 Million | ▼ -397.5% |
| 2007 | -0.42x | $-2.72 Million | $6.46 Million | ▲ +5.7% |
| 2006 | -0.45x | $-2.62 Million | $5.88 Million | ▼ -13.2% |
| 2005 | -0.39x | $-14.57 Million | $36.99 Million | ▼ -103.6% |
| 2004 | -0.19x | $-9.98 Million | $51.60 Million | ▲ +94.7% |
| 2003 | -3.67x | $-26.96 Million | $7.35 Million | ▼ -59.0% |
| 2002 | -2.31x | $-18.16 Million | $7.87 Million | ▼ -41.1% |
| 2001 | -1.64x | $-10.00 Million | $6.12 Million | ▲ +51.2% |
| 2000 | -3.35x | $-8.35 Million | $2.49 Million | ▲ +5.9% |
| 1999 | -3.56x | $-6.84 Million | $1.92 Million | ▲ +35.1% |
| 1998 | -5.49x | $-7.71 Million | $1.40 Million | — |